Really like the sounds of this Artice! Go BMSN
La Mesa's Regen BioPharma at Work on Breast Cancer Vaccine
Regan will conduct research using gene technology developed by Benitec Biopharma.
Posted by Jennifer Vigil (Editor) , August 13, 2013 at 12:00 PM
patch
Comment Recommend
A Regan researcher. The La Mesa company is involved in the search for a cure for breast cancer. Photo credit: ReganBioPharma.com
A Regan researcher. The La Mesa company is involved in the search for a cure for breast cancer. Photo credit: ReganBioPharma.com
Could a vaccine to fight breast cancer be developed in La Mesa?
At the very least La Mesa company Regen BioPharma could play a role, reports the San Diego Daily Transcript. Regen's logo includes the words “fast forwarding stem-cell medicine.”
Popular Stories
Issue: Will Letting Transgender Students Pick Restrooms Do…
Issue: Should Rep. Issa Concede Climate Change Is…
Women Robbed of Purses at Gunpoint on La Mesa Boulevard
Regen, a subsidiary of Bio-Matrix Scientific Group (OTC: BMSN), has a licensing agreement with Benitec Biopharma (ASX: BLT) for vaccines that can be developed using gene technology shaped by Benitec.
Ever worked in a laboratory? Help us decipher the technology they'll be using, according to the report: “the application of ddRNAi to silence indoleamine 2,3 - dioxygenase (IDO) in dendritic cells.”
Huh? Let's break it down a bit. IDO may cause immune suppression and is present when there is cancer. In preliminary work, Regan has shown that altering the cells with ddRNAi could make it more likely for use in the development of a vaccine to fight cancer.
According to a news release, Dr. David Koos, Regen's CEO, said, the work could lead to “an immune-based, non-toxic, cancer treatment initially targeting breast cancer."
The science behind the research has been examined in The Journal of Cancer.
Comment Recommend
AI
